Clinical trials: Malignant Solid Tumours
Malignant Solid Tumor
A Phase I/II Clinical Study of FH-006 for Injection in Patients With Malignant Solid Tumors
This study aims to evaluate the safety, tolerability, pharmacokinetics and immunogenicity of FH-006 in subjects with advanced malignant solid tumors, and determine the preliminary efficacy.
- Trial name
- NCT07136142
- Testing
- FH-006 for Injection, SHR-1316 Injection, Paclitaxel for Injection (Albumin-Bound)
- Where
- 2 sites in China
- Volunteers
- 150 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Advanced Malignant Solid Neoplasm, RAS Mutation
A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies
RSC-101 is a Phase 1a/1b clinical trial of RSC-1255 in adult study participants with advanced solid tumor malignancies who are intolerant of existing therapies known to provide clinical benefit, have disease that has progressed…
- Conditions
- Advanced Malignant Solid Neoplasm, RAS Mutation, Lung Cancer, Colon Cancer
- Trial name
- NCT04678648
- Testing
- RSC-1255 Dose Escalation, RSC-1255 Dose Expansion
- Where
- 3 sites in United States
- Volunteers
- 134 people
- Sponsor
- RasCal Therapeutics, Inc.
Cancer of Colon, Malignant Melanoma
IVIG in the Treatment of Metastatic Cancers of the Prostate, Colon and Melanoma
The purpose of this study is to evaluate the safety and efficacy of IVIG in the treatment of metastatic cancer of the prostate, colon and melanoma.
- Conditions
- Cancer of Colon, Malignant Melanoma, Urologic Cancer
- Trial name
- NCT00294476
- Testing
- IVIG, Biological Therapy
- Where
- 3 sites in Israel
- Volunteers
- 30 people
- Sponsor
- GammaCan
Tumors, Neoplasms
Study Evaluating TTI-237 in Advanced Malignant Solid Tumors.
The purpose of this study is to evaluate the safety, tolerability, and MTD (maximum tolerated dose) of TTI-237 for the treatment of subjects with advanced malignant solid tumors.
- Trial name
- NCT00195325
- Testing
- TTI-237
- Where
- 3 sites in United States
- Volunteers
- 45 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Advanced Malignant Solid Tumor
A Study to Evaluate the Tolerance and Pharmacokinetics of TQB3303 Tablets
TQB3303 tablet is a small molecule oral drug inhibiting cyclin-dependent kinases 4 and 6 (CDK4 / 6). Based on current research, overexpression of positive regulatory proteins in the cell cycle is one of the important reasons for…
- Trial name
- NCT04275050
- Testing
- TQB3303
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Breast Cancer, Breast Neoplasms, Endometrial Cancer, Endometrial Neoplasm
GEN1047 for Solid Tumors - First in Human (FIH) Trial
The purpose of this trial is to measure the following in participants with solid tumors who receive GEN1047: The side effects seen with GEN1047 What the body does with GEN1047 once it is administered What GEN1047 does to the body…
- Conditions
- Breast Cancer, Breast Neoplasms, Endometrial Cancer, Endometrial Neoplasm, Ovarian Cancer, Ovarian Neoplasms, Squamous Non Small Cell Lung Cancer (NSCLC-SCC)
- Trial name
- NCT05180474
- Testing
- GEN1047 is a bispecific antibody that induces T-cell mediated cytotoxicity of B7H4-positive tumor cells.
- Where
- 36 sites in United States, Belgium and 7 more
- Volunteers
- 179 people
- Sponsor
- Genmab
Participants With Advanced Solid Tumor Malignancies
Clinical Trial of VBC103 in Patients With Advanced Malignant Solid Tumors
This study is a multicenter, open-label, multi-dose, first-in-human (FIH) Phase I/IIa study to determine the safety and tolerability of VBC103, as well as the maximum tolerated dose (MTD) and/or recommended Phase II dose (RP2D)…
- Trial name
- NCT07299747
- Testing
- VBC103
- Where
- China
- Volunteers
- 255 people
- Sponsor
- VelaVigo Bio Inc
Locally Advanced Malignant Neoplasm, Malignant Solid Tumour
A Study of ALT-836 in Combination With Gemcitabine for Locally Advanced or Metastatic Solid Tumors
This is a Phase I, open-label, multi-center, competitive enrollment and dose-escalation study of ALT-836 in combination with standard of care gemcitabine in participants who have locally advanced or metastatic solid tumors.
- Trial name
- NCT01325558
- Testing
- ALT-836 in combination with gemcitabine
- Where
- 4 sites in United States
- Volunteers
- 30 people
- Sponsor
- Altor BioScience
Solid Cancer
A Study of AK138D1 in Advanced Malignant Tumors
This is a Phase I clinical trial testing the safety and effectiveness of AK138D1in patients with advanced cancer. The study will enroll up to 200 patients with various types of advanced solid tumors who haven't responded to…
- Trial name
- NCT07281326
- Testing
- AK138D1
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Akeso
Advanced Malignant Solid Tumors
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Efficacy of Cisplatin Micelle Injection (HA132) in Patients With Advanced Malignant Solid Tumors
This is a multicenter, open-label, dose-escalation, dose-expansion, and cohort-expansion Phase I/II clinical study to evaluate safety, tolerability, pharmacokinetics, antitumor efficacy and to determine the maximum tolerated dose…
- Trial name
- NCT05478785
- Testing
- Cisplatin micelle injection (HA132)
- Where
- China
- Volunteers
- 126 people
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Advanced Solid Tumor
Novel mRNA-LNP-Based Intratumoral Immunotherapy in Patients With Advanced Malignant Solid Tumors
PMC2129G12 is an investigational intratumorally administered messenger RNA-lipid nanoparticle (mRNA-LNP) immunotherapy designed to enable localized, transient expression of a humanized EpCAM-targeted CD3-engaging bispecific…
- Trial name
- mRNA-LNP (NCT07587879)
- Testing
- mRNA-LNP
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- IntraAb, Inc.
Solid Tumours
An Extension Study of LON002 in Patients With Cancer
The purpose of this clinical trial is to evaluate the long term safety and efficacy of LON002.
- Trial name
- NCT02390986
- Testing
- LON002
- Where
- 2 sites in United Kingdom
- Volunteers
- 50 people
- Sponsor
- LondonPharma Ltd.
Advanced Malignant Solid Tumors
Safety, Tolerability and Pharmacokinetics Characteristics of Recombinant Oncolytic Vaccinia Virus Injection T601 as a Single Drug or in Combination With Oral Flucytosine (5-FC), in Patients With Advanced Malignant Solid Tumors
This open, dose-escalation and extended PhI/IIa clinical trial aims to evaluate the safety, tolerability of T601 as a single-agent as well as combined with prodrug 5-FC to treat patients with advanced malignant solid tumors and…
- Trial name
- NCT04226066
- Testing
- T601, T601+5-FC
- Where
- 2 sites in China
- Volunteers
- 69 people
- Sponsor
- Tasly Tianjin Biopharmaceutical Co., Ltd.
Malignant Neoplasm
PM8002 in the Treatment of Patients With Advanced Solid Tumors
This study is to characterize the safety, tolerability, pharmacokinetics (PK), immunogenicity, pharmacodynamics (PD) and anti-tumor activity of PM8002, a PD-L1/VEGF bispecific antibody, as a single agent in adult subjects with…
- Trial name
- NCT05918445
- Testing
- PM8002
- Where
- 48 sites in China
- Volunteers
- 380 people
- Sponsor
- Biotheus Inc.
Malignant Tumors
A Study of LM-350 in Subjects With Advanced Solid Tumours
For Phase I Dose Escalation Stage, to assess the safety and tolerability of LM-350 in patients with advanced solid tumors,determine the maximum tolerated dose (MTD) or optimal biological dose (OBD), and explore the relationship…
- Trial name
- NCT07112222
- Testing
- LM-350 for injection
- Where
- 4 sites in Australia, China
- Volunteers
- 80 people
- Sponsor
- LaNova Medicines Limited
Advanced Malignant Solid Tumor
Phase I/II Study of SCTB39-1 in Advanced Solid Tumours
This study aims to evaluate the safety, tolerability, PK characteristics, immunogenicity, and preliminary anti-tumor efficacy of SCTB39-1 as a monotherapy in adult patients with advanced malignant solid tumours.
- Trial name
- NCT07050641
- Testing
- SCTB39-1
- Where
- China
- Volunteers
- 110 people
- Sponsor
- Sinocelltech Ltd.
Advanced Solid Tumor
JSKN033 in Patients With Advanced or Metastatic Solid Malignant Tumors
This study is an open-label, multicenter, first-in-human, Phase I/II (dose escalation and dose expansion) study to evaluate the safety, tolerability, PK, immunogenicity and efficacy of JSKN033 in patients with advanced…
- Trial name
- NCT06226766
- Testing
- JSKN033 Injection
- Where
- Australia
- Volunteers
- 11 people
- Sponsor
- Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Advanced Malignant Solid Tumors
A Study of TPD3310 in Patients With Advanced Malignant Tumors
This study is a multicenter, open phase I clinical study of dose escalation,cohort expansion study to evaluate the safety,tolerability,pharmacokinetics,pharmacodynamics, and preliminary efficacy of TPD3310 in patients…
- Trial name
- NCT07368127
- Testing
- TPD3310 injection
- Where
- China
- Volunteers
- 112 people
- Sponsor
- TAIBIDI PHARMACEUTICAL TECHNOLOGY(SHIJIAZHUANG) CO.,LTD.
Solid Malignancies
Safety and Tolerability of CMAB017 In Patients With Advanced Solid Tumors
This is a multicenter, open-lable phase Ia clinical study to evaluate the safety, tolerability, pharmacokinetic profile and preliminary antitumor activity of CMAB017 in advanced malignant solid tumors.
- Trial name
- NCT06933069
- Testing
- CMAB017
- Where
- China
- Volunteers
- 55 people
- Sponsor
- Taizhou Mabtech Pharmaceutical Co.,Ltd
Neoplasm Malignant
Effect of SAR302503 on ECG Activity in Patients With Solid Tumors
Primary Objective: To assess the effect of SAR302503 (500 mg) administered as 14-day repeated doses on the QTcF interval compared to 1-day placebo in patients with advanced solid tumors.
- Trial name
- NCT01836705
- Testing
- SAR302503 (TG101348), Panolosetron
- Where
- 10 sites in United States, Belgium
- Volunteers
- 60 people
- Sponsor
- Bristol-Myers Squibb